Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development

International Journal of Cancer

Volumn 125, Issue 9, 2009, Pages 2095-2103

  Zieger, Karsten ^a   Marcussen, Niels ^b   Borre, Michael ^a   Ørntoft, Torben F ^a   Dyrskjøt, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Carcinoma in situ; Chromosomal instability; Classification; Oligonucleotide array sequence analysis; Urinary bladder neoplasms

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; FGFR3 PROTEIN, HUMAN;

ADVANCED CANCER; ALLELE; ARTICLE; BLADDER CANCER; CANCER INVASION; CARCINOMA IN SITU; CHROMOSOME 10P; CHROMOSOME 13P; CHROMOSOME 5P; CONTROLLED STUDY; DISEASE MARKER; DNA MICROARRAY; DYSPLASIA; GENE MUTATION; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BLADDER TUMOR; CHROMOSOME ABERRATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETICS; MUTATION; PATHOLOGY;

CARCINOMA IN SITU; CHROMOSOME ABERRATIONS; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS;

EID: 70249110104     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24619     Document Type: Article

References (47)

1. Wolf H, Olsen PR, Fischer A, Hojgaard K. Urothelial atypia concomitant with primary bladder tumour. Incidence in a consecutive series of 500 unselected patients. Scand J Urol Nephrol 1987;21:33-38 (Pubitemid 17028546)
2. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 2007;51:152-160 (Pubitemid 44821530)
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouf-fioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-475
4. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-96. (Pubitemid 36068689)
5. Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 2003;12(Spec No 2):R153-R157. (Pubitemid 37259327)
6. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006;24:5079-5090 (Pubitemid 46631412)
7. Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La PB, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006;131:729-737 (Pubitemid 44307064)
8. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040-4048 (Pubitemid 38697320)
9. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmstrom PU, de la TM, Wester K, Allory Y, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13:3545-3551 (Pubitemid 46955114)
10. Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D, Simon R, Knuechel R, Pilarsky C, Hartmann A. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11:4415-4429 (Pubitemid 40825632)
11. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-373
12. Billerey C, Chopin D, ubriot-Lorton MH, Ricol D, Gil Diez de MS, Van RB, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-1959.
13. Spruck CH, III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-788 (Pubitemid 24068337)
14. Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, Waldman FM. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 1995;26: 970-978
15. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995;55:5213-5216
16. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, Knuechel R. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002;62:809-818 (Pubitemid 34126958)
17. Hopman AH, Kamps MA, Speel EJ, Schapers RF, Sauter G, Ramaekers FC. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 2002;161:1119-1125
18. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Orntoft TF. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005;11:7709-7719 (Pubitemid 41611613)
19. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004;20:1233-1240 (Pubitemid 38807579)
20. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004;64:3060-3071 (Pubitemid 38581405)
21. Dyrskjot L, Zieger K, Kruhoffer M, Thykjaer T, Jensen JL, Primdahl H, Aziz N, Marcussen N, Moller K, Orntoft TF. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029-4036 (Pubitemid 40791566)
22. Aaboe M, Marcussen N, Jensen KM, Thykjaer T, Dyrskjot L, Orntoft TF. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer 2005;93:1182-1190 (Pubitemid 41670704)
23. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boeve ER, Jobsis AC, Zwarthoff EC. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-1921 (Pubitemid 46606378)
24. van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 2007;52:760-768 (Pubitemid 47126132)
25. Hanahan D, Weinberg RA. The hallmarks of cancer Cell 2000;100: 57-70.
26. Lamy A, Gobet F, Laurent M, Blanchard F, Varin C, Moulin C, Andreou A, Frebourg T, Pfister C. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006;176(6 Part 1):2686-2689 (Pubitemid 44755065)
27. Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, Libertino JA, Summerhayes IC. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003;98:737-744 (Pubitemid 36959269)
28. Burchill SA, Neal DE, Lunec J. Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Br J Urol 1994;73:516-521 (Pubitemid 24190155)
29. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181 (Pubitemid 46316032)
30. Oh WJ, Rishi V, Pelech S, Vinson C. Histological and proteomic analysis of reversible H-RasV12G expression in transgenic mouse skin. Carcinogenesis 2007;28:2244-2252 (Pubitemid 47543387)
31. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-8112 (Pubitemid 37549454)
32. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, Zwarthoff EC. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64:1911-1914
33. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, Amoros A, Tardon A, Garcia-Closas R, Serra C, Carrato A, Malats N, Real FX. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 2005;11:5444-5450 (Pubitemid 41060820)
34. Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2:502-510 (Pubitemid 41594404)
35. Hoglund M, Sall T, Heim S, Mitelman F, Mandahl N, Fadl-Elmula I. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res 2001;61:8241-8246 (Pubitemid 33091618)
36. Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia 2008;10:1-7. (Pubitemid 351170708)
37. Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genomewide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 2003;63:2216-2222 (Pubitemid 36538629)
38. Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, von der MH, Orntoft TF. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 2005;65:34-45. (Pubitemid 40070793)
39. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-447 (Pubitemid 29160005)
40. van Oers JM, Adam C, Denzinger S, Stoehr R, Bertz S, Zaak D, Stief C, Hofstaedter F, Zwarthoff EC, van der Kwast TH, Knuechel R, Hartmann A. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006;119:1212-1215 (Pubitemid 44116931)
41. Zheng M, Simon R, Mirlacher M, Maurer R, Gasser T, Forster T, Diener PA, Mihatsch MJ, Sauter G, Schraml P. TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol 2004;165:63-69 (Pubitemid 38821814)
42. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998;153:1615-1621 (Pubitemid 28509919)
43. Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ, Sauter G. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004;23: 5616-5623 (Pubitemid 39093039)
44. Primdahl H, von der MH, Christensen M, Wolf H, Orntoft TF. Allelic deletions of cell growth regulators during progression of bladder cancer. Cancer Res 2000;60:6623-6629
45. Kim MS, Jeong J, Majewski T, Kram A, Yoon DS, Zhang RD, Li JZ, Ptaszynski K, Kuang TC, Zhou JH, Sathyanarayana UG, Tuziak T, et al. Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia. Lab Invest 2006;86:175-190 (Pubitemid 43117597)
46. Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997;57:2860-2864 (Pubitemid 27315028)
47. Badoual C, Bouchaud G, Agueznay NH, Mortier E, Hans S, Gey A, Fernani F, Peyrard S, Puig PL, Bruneval P, Sastre X, Plet A, et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008;68:3907-3914